Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys

  title={Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys},
  author={David R. Schulze and F. Ivy Carroll and Lance R. McMahon},
RationaleΔ9-tetrahydrocannabinol (Δ9-THC) modifies dopamine efflux. However, the extent to which cannabinoid and dopamine drugs modify each other’s behavioral effects has not been fully established.ObjectivesThis study examined dopamine releasers and/or transport inhibitors alone and in combination with cannabinoids in two drug discrimination assays.MethodsExperimentally and pharmacologically experienced rhesus monkeys (n = 5) discriminated Δ9-THC (0.1 mg/kg i.v.) from vehicle while responding… 
Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function
Examination of brain-specific rictor knockout mouse model of impaired neuronal phosphorylation of Akt reveals that defective central Akt function alters 5-HT signaling as well as5-HT-associated behaviors, demonstrating a novel role for Akt in maintaining neuronal 5- HT receptor function.
Modulation of the Endogenous Cannabinoid System as a Therapeutic Target in the Treatment of Mental Health Disorders
The endogenous cannabinoid system and its natural ligands are reviewed, along with how this system could potentially be involved in affective disorders, anxiety disorders, and schizophrenia.
Discriminative Stimulus Properties of S(-)-Nicotine: "A Drug for All Seasons".
The usefulness of the procedure to study nicotine, a general overview of the model, and some relevant methodological details for the establishment of this drug as a stimulus are presented.
Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System
Evidence indicates that several classes of pharmaceuticals upregulate the eCB system, including analgesics, non-steroidal anti-inflammatory drugs, opioids, glucocorticoids, antidepressants, antipsychotics, anxiolytics, and anticonvulsants.
Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management
With the legalization of marijuana in many states, CHS will become an increasingly prevalent clinical entity, so educating about CHS is an important goal, particularly for emergency department physicians who generally first encounter these patients.
Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome
It is reported that 4 cases of CHS that failed standard emergency department therapy but improved significantly after treatment with haloperidol are reported, warranting further investigation of haloperIDol as an emergency department treatment for CHS.
Cannabinoid Hyperemesis Syndrome: An Emerging Drug-Induced Disease.
Symptoms of cannabinoid hyperemesis resolve with cannabis cessation and recur when cannabis use is reinitiated, supporting an association between chronic use and cyclic vomiting.
Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.
  • J. Richards
  • Medicine
    The Journal of emergency medicine
  • 2018
The pathophysiology of Cannabinoid hyperemesis syndrome is investigated and the published literature on pharmacologic treatment in the emergency department is evaluated to provide evidence-based, efficacious anti-emetic treatment grounded in knowledge of antiemetic medications' mechanisms of action.
Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review
Cannabinoid hyperemesis syndrome is a cyclic vomiting syndrome, preceded by daily to weekly cannabis use, usually accompanied by symptom improvement with hot bathing, and resolution with cessation of cannabis, which appears to be the best treatment.
In Response to: Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review
Although I am certain haloperidol is unlikely to work in all patients, I am convinced it works often enough to warrant further investigation to determine optimal dosing, optimal timing, and the appropriate target patient.


Rimonabant-Induced Δ9-Tetrahydrocannabinol Withdrawal in Rhesus Monkeys: Discriminative Stimulus Effects and Other Withdrawal Signs
This study characterized rimonabant-induced Δ9-tetrahydrocannabinol (Δ9-THC) withdrawal in rhesus monkeys by using drug discrimination and directly observable signs and suggested that cannabinoid and noncannabinoid (α2-adrenergic) agonists are potentially useful therapeutics for marijuana dependence inasmuch as they attenuate the subjective experience of cannabinoid withdrawal.
Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D2-induced formation of anandamide
Dopamine does not play a major role in THC discrimination, however, activation of the dopaminergic system positively modulates the discriminative effects of THC, possibly through D2-induced elevations in brain levels of anandamide.
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys
The results indicate that the rate of drug entry in brain can play an important role in the behavioral pharmacology of psychomotor stimulants.
Mesolimbic dopaminergic decline after cannabinoid withdrawal.
Data indicate that withdrawal from chronic cannabinoid administration is associated with reduced dopaminergic transmission in the limbic system, similar to that observed with other addictive drugs; these changes in neuronal plasticity may play a role in drug craving and relapse into drug addiction.
Characterization of Cannabinoid Agonists and Apparent pA2 Analysis of Cannabinoid Antagonists in Rhesus Monkeys Discriminating Δ9-Tetrahydrocannabinol
  • L. McMahon
  • Chemistry, Medicine
    Journal of Pharmacology and Experimental Therapeutics
  • 2006
The results demonstrate that the discrim inative stimulus effects of Δ9-THC are selective for cannabinoid activity, and the results of Schild analysis suggest that the same receptors mediate the discriminative stimulus results of Δ 9-THc, CP 55940, and WIN 55212-2.
Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans
Abstract. Rationale: Data obtained in laboratory animals and humans suggest that dopamine D1 receptor antagonists decrease cocaine self-administration and block cocaine's discriminative stimulus and
Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats
D dose-dependently produced catalepsy, decreased locomotion, and reduced the amplitude of electrically evoked dopamine release while markedly increasing the frequency of detected (nonstimulated) dopamine concentration transients is demonstrated.
A pharmacological analysis of the discriminative stimulus properties of d-amphetamine in rhesus monkeys.
Rhesus monkeys (n = 4) were trained to discriminate d-amphetamine from saline in a two lever, food-reinforced drug discrimination paradigm and tested with a series of compounds selected to characterize the neuronal mechanism(s) of the discrimination.
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis
Evidence is given for the existence of antagonistic CB(1)/D(2) receptor-receptor interactions within CB( 1)/D (2) heteromers in which A(2A) receptors may also participate.
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
Delta9-THC and heroin exert similar effects on mesolimbic dopamine transmission through a common mu1 opioid receptor mechanism located in the ventral mesencephalic tegmentum.